Dr. Palmer on the Treatment Landscape of aGVHD

Video

In Partnership With:

Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.

Jeanne M. Palmer, MD, a hematologist and oncologist in the Department of Hematology and Bone Marrow Transplant Program at Mayo Clinic, discusses the current treatment landscape of acute graft-versus-host disease (aGVHD).

Steroids, such as methylprednisolone or prednisone, remain the mainstay of first-line ​treatment for patients with aGVHD treatment, says Palmer.

At the start of treatment, patients typically receive a ​steroid dose of 0.50 mg/kg to 2 mg/kg​, says Palmer. ​As long as patients are responding, the ​dose is ​typically decreased over time.

Patients who do not have an adequate response after 3 to 5 days ​of treatment are considered steroid refractory, Palmer adds.

Several second-line treatment options are available to ​treat patients with steroid-refractory ​disease. However, there are no​ robust data ​to indicate which option is superior, says Palmer. 

Finally, ​it ​is critical to remember that ​data from single-center studies may not be as compelling as multi-center studies, Palmer concludes.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD